Company Overview
Company Type: Public Company
Website: www.wpdpharmaceuticals.com
Number of Employees: 19
Ticker: WBIO (CNSX)
Year Founded: -


Business Description
WPD Pharmaceuticals Inc., a biotechnology research and development company, engages in the research and development of medicinal products in the fields of oncology and infectious diseases. It develops WPD101 to treat brain cancers; WPD102 for the treatment of uveal melanoma; Berubicin to treat glioblastoma multiforme; and WP1066 for the treatment of glioblastoma and melanoma brain metastases. The company is also developing WP1220 for the treatment of cutaneous T-cell lymphoma; WPD103, a radiopharmaceutical based on the expression of tumor-specific receptors, such as IL-13RA2 and EphA2; and Annamycin to treat solid tumors metastasis to lungs. WPD Pharmaceuticals Inc. is headquartered in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
5.1
EBITDA
(6.0)
EBIT
(6.5)
Cash & ST Invst.
0.6
P/Diluted EPS Before Extra
NM
Net Income
(4.9)
Total Debt
0.3
Price/Tang BV
NM
Capital Expenditure
0.0
Total Assets
2.1
Total Debt/EBITDA
NM


Currency in CAD in mm, LTM as of Sep-30-2021 TEV and Market Cap are calculated using a close price as of Jul-11-2022

Key Professionals
Name
Title
Olejniczak, Mariusz 
Chief Executive Officer
Priebe, Waldemar 
Founder & Chairman of Scientific Advisory Board
Suchoszek, Katarzyna 
Chief Operating Officer
Pajak, Beata 
Chief Scientific Officer
Sipowicz, Marek 
Chief Medical Officer

Key Board Members
Name
Title
Priebe, Waldemar 
Founder & Chairman of Scientific Advisory Board
Carmichel, Constantine 
Director
Debinski, Waldemar 
Member of Scientific Advisory Board
Harwas, Romuald Apollo
Director
Luksha, Nicholas 
Director
Novak, Peter 
Independent Director
Rzepczyk, Teresa Liliana
Independent Director
Walling, John A.
Member of Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
789 West Pender Street Suite 401 | Vancouver, BC | V6C 2T7 | Canada
Fax: 604 565 3332


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Westcot Ventures Corp.
As of December 20, 2019, Westcot Ventures Corp. was acquired by WPD Pharmaceuticals sp. z o.o., in a reverse merger transaction. Westcot Ventures Corp. engages in the acquisition, exploration, and development of mineral properties. The company was formerly known as Sparrow Ventures Corp. and changed its name to Westcot Ventures Corp. in September 2017. Westcot Ventures Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.

United States and Canada
Diversified Metals and Mining
-
2.00
0.00
WPD Pharmaceuticals Sp zoo
WPD Pharmaceuticals Sp zoo develops biological and chemical molecules involved in targeted therapy for brain glioma and other central nervous system cancer treatment. The company is headquartered in Warsaw, Poland with an additional location in Vancouver, Canada. The company operates as a subsidiary of Houston Pharmaceuticals, Inc.

Europe
Biotechnology
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-01-2023
Jun-15-2023
Private Placement
Target
WPD Pharmaceuticals Inc. (CNSX:WBIO)


0.23
May-02-2019
Dec-20-2019
Merger/Acquisition
Buyer
Westcot Ventures Corp.
WPD Pharmaceuticals Inc. (CNSX:WBIO)

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jun-15-2023
Private Placements
WPD Pharmaceuticals Inc. announced that it has received CAD 0.3 million in funding
May-03-2023
Company Conference Presentations
WPD Pharmaceuticals Inc. Presents at Outsourcing In Clinical Trials Europe 2023, May-03-2023
May-01-2023
Executive/Board Changes - Other
WPD Pharmaceuticals Inc. Announces Directorate Appointments
May-01-2023
Product-Related Announcements
WPD Pharmaceuticals Inc. Provides Update on Research Project Pipeline
May-01-2023
Private Placements
WPD Pharmaceuticals Inc. announced that it expects to receive CAD 0.3 million in funding


Advisors
Most Recent Auditor
Davidson & Company LLP


Most Recent Auditor
Davidson & Company


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Infinata, Inc.
Infinata Research
Aug 11, 2020 07:19 AM
WBIO
WPD Pharmaceuticals sp. z o.o - Company Report
Reports
11
Infinata, Inc.
Infinata Research
Jun 10, 2020 09:11 AM
WBIO
WPD Pharmaceuticals sp. z o.o - Company Report
Reports
11
Infinata, Inc.
Infinata Research
Mar 11, 2020 04:24 AM
WBIO
WPD Pharmaceuticals sp. z o.o - Company Report
Reports
9
Infinata, Inc.
Infinata Research
Dec 16, 2019 05:41 AM
WBIO
WPD Pharmaceuticals sp. z o.o - Company Report
Reports
9
Infinata, Inc.
Infinata Research
Sep 30, 2019 05:48 AM
WBIO
WPD Pharmaceuticals sp. z o.o - Company Report
Reports
9
Infinata, Inc.
Infinata Research
Jun 10, 2019 06:46 AM
WBIO
WPD Pharmaceuticals sp. z o.o - Company Report
Reports
9
Infinata, Inc.
Infinata Research
Mar 11, 2019 04:52 AM
WBIO
WPD Pharmaceuticals sp. z o.o - Company Report
Reports
8


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Caelum Finance Ltd, Asset Management Arm

2,200,000

1.94

0.1

Mar-23-2023



 


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Annamycin (Future), Berubicin (Future), Licensing of WP1122, Licensing of WP1732, WP101 (Future), WP104 (Future), WP1066 (Future), WP1122 (Future), WP1220 (Future), WP1732 (Future), WPD102, WPD103


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
Sep-08-2023
WPD Pharmaceuticals Inc. (CNSX:WBIO)
SEDAR
News Releases
138 KB
Sep-01-2023
WPD Pharmaceuticals Inc. (CNSX:WBIO)
SEDAR
News Releases
135 KB
Aug-09-2023
WPD Pharmaceuticals Inc. (CNSX:WBIO)
SEDAR
News Releases
124 KB
Jun-20-2023
WPD Pharmaceuticals Inc. (CNSX:WBIO)
SEDAR
Material Change Report
202 KB
Jun-15-2023
WPD Pharmaceuticals Inc. (CNSX:WBIO)
SEDAR
News Releases
127 KB
May-05-2023
WPD Pharmaceuticals Inc. (CNSX:WBIO)
SEDAR
Material Change Report
218 KB
May-01-2023
WPD Pharmaceuticals Inc. (CNSX:WBIO)
SEDAR
News Releases
142 KB
Apr-21-2023
WPD Pharmaceuticals Inc. (CNSX:WBIO)
SEDAR
Material Change Report
226 KB
Jan-18-2023
WPD Pharmaceuticals Inc. (CNSX:WBIO)
SEDAR
News Releases
112 KB
Dec-19-2022
WPD Pharmaceuticals Inc. (CNSX:WBIO)
SEDAR
News Releases
106 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Cherry C.A., C.P.A., CA, CGA, CPA, Christopher P. (Former CFO & Director)
Jan-14-2020
Options
500,000
0
Derivative Acquisition Under Employee Benefit Plan
New
Exchange Announcement
Klemp, Walter V. (Former Independent Director)
Jan-13-2020
Options
750,000
0
Derivative Acquisition Under Employee Benefit Plan
New
Exchange Announcement
Corcoran, Liam Lake (Former Director)
Jan-13-2020
Options
700,000
0
Derivative Acquisition Under Employee Benefit Plan
New
Exchange Announcement
Rzepczyk, Teresa Liliana (Independent Director)
Jan-13-2020
Options
200,000
0
Derivative Acquisition Under Employee Benefit Plan
New
Exchange Announcement
Olejniczak, Mariusz  (Chief Executive Officer)
Jan-13-2020
Options
1,000,000
0
Derivative Acquisition Under Employee Benefit Plan
New
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Priebe, Waldemar 
Founder & Chairman of Scientific Advisory Board
-
604 565 3332

Carmichel, Constantine 
Director
-
604 565 3332

Debinski, Waldemar 
Member of Scientific Advisory Board
-
604 565 3332

Harwas, Romuald Apollo
Director
-
604 565 3332

Luksha, Nicholas 
Director
604-838-0184
604 565 3332

Novak, Peter 
Independent Director
-
604 565 3332

Rzepczyk, Teresa Liliana
Independent Director
-
604 565 3332

Walling, John A.
Member of Scientific Advisory Board
-
604 565 3332

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Olejniczak, Mariusz 
Chief Executive Officer
-
604 565 3332

Priebe, Waldemar 
Founder & Chairman of Scientific Advisory Board
-
604 565 3332

Suchoszek, Katarzyna 
Chief Operating Officer
-
604 565 3332

Pajak, Beata 
Chief Scientific Officer
-
604 565 3332

Sipowicz, Marek 
Chief Medical Officer
-
604 565 3332

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
